Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: In a study in the medical journal The Lancet, they said the patients, with strains of TB known as extensively-drug resistant (XDR) and totally drug resistant (TDR) TB, have exhausted all available treatment options and are sent home. “These patients can survive for months or even years and are contributing to the community-based spread of XDR-TB,” said Keertan Dheda, who led the study at the University of Cape Town’s department of medicine. Tuberculosis infects the lungs and can spread through coughing and sneezing. In recent years, drug-resistant strains have spread around the world, batting off standard antibiotics and posing an increasingly urgent public health threat. The World Health Organization (WHO) estimates that in Eastern Europe, Asia and South Africa, 450,000 people have MDR-TB, and around half of these will fail to respond to existing treatments. Dheda’s team followed 107 patients with XDR-TB from three provinces in South Africa between March 2008 and August 2012 to establish their fate. They also took samples from 56 patients and tested them to find out which and how many of 10 first- and second-line anti-TB drugs they were susceptible to. Despite being treated intensively with an average of eight anti-tuberculosis drugs, many of the patients fared poorly, with high rates of treatment failure and death. Five years after treatment initiation, only 12 of the patients had favorable outcomes and 74 percent had died. The researchers found that almost two-thirds of the tested patients had resistance to at least eight drugs, and there was one case of totally drug-resistant TB that was not susceptible to any of the 10 drugs tested. More worrisome, Dheda said, was that of the XDR-TB patients discharged into the general community, some 42 percent had failed to get better on treatment and were testing positive for active TB, and of these almost a third were at high risk of transmitting the disease. The patients also survived in the community for an average of 20 months - plenty of time to infect others. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. Another person needs to inhale only a few of these germs to become infected. “Alarmingly, we have shown for the first time that... treatment failure and discharge of such patients into the wider community is occurring systematically on a country-wide level in South Africa,” Dheda said in a statement about the findings. In one case where the researchers followed a genetic trail of transmission, they found that a patient with XDR-TB who was discharged after failing treatment went on to infect his brother, who also eventually died. Dheda said the reason many TB patients are being sent away from hospitals appeared to be lack of bed space in designated tuberculosis hospitals. “And alternative long-term residential and palliative care facilities are scarce.”  Commenting on the findings in The Lancet, Max O’Donnell from New York’s Albert Einstein College of Medicine in the United States said they should serve as an “urgent alarm”. “MDR-TB (multi-drug-resistant TB) in all its forms is an out-of-control problem with potentially vast and devastating consequences for global public health,” he wrote. “The situation regarding MDR and XDR-TB is bleak.”
Example Output: South Africa risks spreading totally drug-resistant TB: study.

Example Input: Bottles of Corona beer speed past a worker in the bottling line of Mexico City's Modelo brewery, May 19, 2004. REUTERS/Andrew Winning He may be in for worse than a surprise: a nasty skin reaction that one doctor is calling “Mexican beer dermatitis.”   A substance in lime juice, if left on the skin in the sun, can cause the skin to become discolored, as if by poison ivy or a jellyfish sting — and the marks can last for months, reports Scott Flugman in the Archives of Dermatology. Mexican beers, particularly Corona, are typically served with a lime slice wedged in the top of the bottle. The drinker shoves the lime into the bottle and holds his or her thumb over the bottle’s mouth while turning the bottle over to mix in the juice. But if the drinker is not careful, the beer’s carbonation can spray lime juice and beer all over his or her skin — “especially in a patient who is shirtless by a beach or pool,” wrote Flugman, a dermatologist in New York. The resulting reaction is due to a substance called psoralen, used to make the skin more sensitive to a wavelength of ultraviolet light, UV-A, used to treat certain skin conditions. Lemons contain psoralens too, but not as strong. “It’s just a cosmetic issue,” Flugman told Reuters Health, though he said the discoloration — most frequently in people like bartenders who work outdoors with limes — may take an emotional toll. “People are worried that it’s something serious. You might have some brown spots you’re been looking at for a few months,” he said. Olive-skinned Caucasians may be especially susceptible. No ties have been shown between the reaction and skin cancer, said Flugman, who added that he sees two or three cases a year. They are often mystified why a dermatologist is asking them if they’ve recently drunk Mexican beer. His advice? “If you do this and you spritz the beer or the lime, just wash it off. Don’t leave it on there and sit out in the sun,” he said. Or, if you are disinclined to get up for a while, “throw a towel over it.”
Example Output: Hold the lime with Corona, may cause skin reaction.

Example Input: The results marked the third successful Phase III test of the drug evolocumab reported by Amgen in recent months - this one in a patient population among the most in need of alternative therapies. An estimated five to 20 percent of heart patients are intolerant of statin medications for lowering cholesterol due to side effects such as muscle weakness or fatigue, Amgen said. Evolocumab belongs to a class of medicine called PCSK9 inhibitors that work by blocking a protein that reduces the liver’s ability to remove LDL cholesterol from the blood. Based on dramatic LDL lowering demonstrated by Amgen and other companies in earlier studies, PCSK9 inhibitors could be the most important new heart drugs to come along in several years with multibillion-dollar sales potential. The injected medicines are likely to be used in high risk heart patients unable to lower their LDL levels sufficiently with high doses of widely used statin drugs, such as Pfizer’s Lipitor, and in those unable to take statins. Many patients remain at high risk of heart attack and stroke “despite the use of all available therapies,” Amgen research and development chief Sean Harper said in a telephone interview. “The ability to treat those individuals with a completely distinct mechanism and see this very large effect size of dropping LDL cholesterol by roughly 50 percent, that’s a pretty big deal for those patients,” Harper said. The company expects during the current quarter to have results of its final two Phase III studies - one in patients already taking high doses of statins and one in patients genetically predisposed to dangerously high cholesterol levels. Amgen will provide details of its latest 307-patient Phase III study, called GAUSS-2, which compared evolocumab to Merck & Co’s Zetia (ezetimibe), at an upcoming medical meeting. However, the world’s largest biotech company said the percentage of cholesterol lowering was consistent with those observed in a similar, smaller Phase II trial. In that study, evolocumab led to 51 percent reduction in LDL levels and 63 percent when combined with Zetia versus a 15 percent reduction seen with Zetia alone. “It’s very unusual to have a therapeutic that addresses one of the underlying factors that drive the greatest mortality risk that exists in Western countries, and increasingly in developing countries - cardiovascular disease driven by atherosclerosis,” Harper said. The company anticipates that some of its global filings seeking approval of the drug will occur this year. “We don’t come across therapeutics like this very often in this industry,” Harper said. “It is very exciting, and as we get each data set our confidence slowly builds that we have the efficacy and the safety profile that will make this an important medicine.”  Regeneron Pharmaceuticals Inc, in partnership with Sanofi, is also in Phase III testing of a rival drug. Pfizer is developing its own PCSK9 inhibitor. Amgen shares were down about 0.6 percent at $123.55 on Nasdaq, roughly in line with declines in the broader market.
Example Output:
Amgen cholesterol drug meets goal of 3rd late stage trial.